Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.11.6525 on July 23 2007

Journal of Clinical Oncology, Vol 25, No 24 (August 20), 2007: pp. 3746-3752
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallamini, A.
Right arrow Articles by Levis, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallamini, A.
Right arrow Articles by Levis, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study

Andrea Gallamini, Martin Hutchings, Luigi Rigacci, Lena Specht, Francesco Merli, Mads Hansen, Caterina Patti, Annika Loft, Francesco Di Raimondo, Francesco D'Amore, Alberto Biggi, Umberto Vitolo, Caterina Stelitano, Rosario Sancetta, Livio Trentin, Stefano Luminari, Emilio Iannitto, Simonetta Viviani, Ivana Pierri, Alessandro Levis

From the Departments of Hematology and Nuclear Medicine, Azienda Ospedaliera S. Croce e Carle, Cuneo; Oncology Department, Università di Firenze, Firenze; Hematology Department, Arcispedale S. Maria Nuova, Reggio Emilia; Hematology Department, Azienda Ospedaliera Cervello, Palermo; Hematology Department, Università di Catania, Catania; Hematology Department, Aarhus University Hospital, Aarhus; Hematology Department, Azienda Ospedaliera S. Giovanni Battista, Torino; Hematology Department, Azienda Ospedaliera Melacrino, Reggio Calabria; Hematology Department, Ospedale S. Giovanni e Paolo ASL 12, Venezia; Experimental Medicine Department, Università di Padova, Padova; Oncology Department, Università di Modena e Reggio Emilia, Modena; Onco-hematology Department, Istituto Nazionale Tumori, Milano; Università di Genova, Genova; Hematology Department, Azienda Ospedaliera S. Antonio e Biagio, Alessandria, Italy; and the Departments of Oncology, Clinical Physiology, Nuclear Medicine, and Positron Emission Tomography, Copenhagen University Hospital, Copenhagen, Denmark

Address reprint requests to Andrea Gallamini, MD, Hematology Department, Azienda Ospedaliera S. Croce e Carle, Via M. Coppino, 26, 12100 Cuneo, Italy; e-mail: andrea.gallamini{at}agx.it

Purpose Starting from November 2001, 260 newly diagnosed patients with Hodgkin's lymphoma (HL) were consecutively enrolled in parallel Italian and Danish prospective trials to evaluate the prognostic role of an early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and the International Prognostic Score (IPS) in advanced HL, treated with conventional ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy.

Patients and Methods Most patients (n = 190) presented with advanced disease (stages IIB through IVB), whereas 70 presented in stage IIA with adverse prognostic factors. All but 11 patients were treated with standard ABVD therapy followed by consolidation radiotherapy in case of bulky presentation or residual tumor mass. Conventional radiologic staging was performed at baseline. FDG-PET scan was performed at baseline and after two courses of ABVD (PET-2). No treatment change was allowed on the basis of the PET-2 results.

Results After a median follow-up of 2.19 years (range, 0.32 to 5.18 years), 205 patients were in continued complete remission and two patients were in partial remission. Forty-three patients progressed during therapy or immediately after, whereas 10 patients relapsed. The 2-year progression-free survival for patients with positive PET-2 results was 12.8% and for patients with negative PET-2 results was 95.0% (P < .0001). In univariate analysis, the treatment outcome was significantly associated with PET-2 (P < .0001), stage IV (P < .0001), WBC more than 15,000 (P < .0001), lymphopenia (P < .001), IPS as a continuous variable (P < .0001), extranodal involvement (P < .0001), and bulky disease (P = .012). In multivariate analyses, only PET-2 turned out to be significant (P < .0001).

Conclusion PET-2 overshadows the prognostic value of IPS and emerges as the single most important tool for planning of risk-adapted treatment in advanced HL.

published online ahead of print at www.jco.org on July 23, 2007.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plutschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
Ann. Onc., July 1, 2009; 20(7): 1270 - 1274.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
D.J. Sher, P.M. Mauch, A. Van Den Abbeele, A.S. LaCasce, J. Czerminski, and A.K. Ng
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy
Ann. Onc., June 18, 2009; (2009) mdp071v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Meignan, E. Itti, S. Bardet, J. Lumbroso, V. Edeline, P. Olivier, T. V. Borght, O. Reman, G. Karcher, O. Mundler, et al.
Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma Trials
J. Clin. Oncol., June 1, 2009; 27(16): 2739 - 2741.
[Full Text] [PDF]


Home page
JNMHome page
M. Hutchings and S. F. Barrington
PET/CT for Therapy Response Assessment in Lymphoma
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
J. Clin. Oncol., April 10, 2009; 27(11): 1906 - 1914.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. Cheson
The Case Against Heavy PETing
J. Clin. Oncol., April 10, 2009; 27(11): 1742 - 1743.
[Full Text] [PDF]


Home page
JNMHome page
E. Itti, C. Lin, J. Dupuis, G. Paone, D. Capacchione, A. Rahmouni, C. Haioun, and M. Meignan
Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
J. Nucl. Med., April 1, 2009; 50(4): 527 - 533.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
Haematologica, April 1, 2009; 94(4): 550 - 565.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Federico, S. Luminari, E. Iannitto, G. Polimeno, L. Marcheselli, A. Montanini, A. La Sala, F. Merli, C. Stelitano, S. Pozzi, et al.
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
J. Clin. Oncol., February 10, 2009; 27(5): 805 - 811.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. M. Carella, M. Bellei, P. Brice, C. Gisselbrecht, G. Visani, P. Colombat, F. Fabbiano, A. Donelli, S. Luminari, P. Feugier, et al.
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results
Haematologica, January 1, 2009; 94(1): 146 - 148.
[Full Text] [PDF]


Home page
BloodHome page
C. Kobe, M. Dietlein, J. Franklin, J. Markova, A. Lohri, H. Amthauer, S. Klutmann, W. H. Knapp, J. M. Zijlstra, A. Bockisch, et al.
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Blood, November 15, 2008; 112(10): 3989 - 3994.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
I. Biasoli, P. Franchi-Rezgui, D. Sibon, J. Briere, E. de Kerviler, C. Thieblemont, V. Levy, C. Gisselbrecht, and P. Brice
Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy
Ann. Onc., November 1, 2008; 19(11): 1915 - 1920.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Suh, Y.-K. Kang, J.-L. Roh, M. R. Kim, J. S. Kim, J. Huh, J. H. Lee, Y. J. Jang, and B.-J. Lee
Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck
J. Nucl. Med., November 1, 2008; 49(11): 1783 - 1789.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A. Jacobs, S. H. Swerdlow, J. Kant, K. A. Foon, R. Jankowitz, S. R. Land, N. DeMonaco, J. Joyce, J. L. Osborn, T. L. Evans, et al.
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma
Clin. Cancer Res., November 1, 2008; 14(21): 7088 - 7094.
[Abstract] [Full Text] [PDF]


Home page
ImagingHome page
A V Martin and B Sharma
Positron emission tomography and CT in the management of lymphoma
Imaging, September 1, 2008; 20(3): 169 - 175.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein
Imaging in staging of malignant lymphoma: a systematic review
Blood, January 15, 2008; 111(2): 504 - 516.
[Abstract] [Full Text] [PDF]


Home page
JWatch Oncology and HematologyHome page
PET and Prognosis in Hodgkin Lymphoma: Prospective Analysis
Journal Watch Oncology and Hematology, September 18, 2007; 2007(918): 2 - 2.
[Full Text]


Home page
ASH Education BookHome page
S. J. Horning
Risk, Cure and Complications in Advanced Hodgkin Disease
Hematology, January 1, 2007; 2007(1): 197 - 203.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online